Abstract
One of the most important features of liver cirrhosis is the splanchnic and systemic arterial vasodilation, related to an increase in vascular capacity and an active vasodilation. This arterial vasodilation seems to be the consequence of the excessive generation of vasodilating substances, which also contributes to a lower than normal pressor response to circulating nervous or humoral substances. The following review analyzes the mechanisms responsible for the vascular hyporesponse to vasoconstrictors observed in the experimental models of liver cirrhosis. It has become increasingly clear that, among the great variety of substances studied, nitric oxide (NO) seems to be one of the main contributors to this vascular alteration, since elimination of the endothelium or inhibition of its synthesis corrects it. The mechanism by which NO interferes with the contractile apparatus in smooth muscle cells seems to be related to a direct effect on calcium entry from the extracellular space and release from the internal stores.
Keywords: endothelium, smooth muscle cells, nitric oxide, liver cirrhosis, vasoconstrictors, vasodilation, portal hypertension
Current Vascular Pharmacology
Title: Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis
Volume: 3 Issue: 1
Author(s): Noemi M. Atucha, F. Javi A. Nadal, David Iyu, Antonia Alcaraz, Alicia Rodriguez-Barbero, M. Clara Ortiz, Jose Miguel Lopez-Novoa and Joaquin Garcia-Estan
Affiliation:
Keywords: endothelium, smooth muscle cells, nitric oxide, liver cirrhosis, vasoconstrictors, vasodilation, portal hypertension
Abstract: One of the most important features of liver cirrhosis is the splanchnic and systemic arterial vasodilation, related to an increase in vascular capacity and an active vasodilation. This arterial vasodilation seems to be the consequence of the excessive generation of vasodilating substances, which also contributes to a lower than normal pressor response to circulating nervous or humoral substances. The following review analyzes the mechanisms responsible for the vascular hyporesponse to vasoconstrictors observed in the experimental models of liver cirrhosis. It has become increasingly clear that, among the great variety of substances studied, nitric oxide (NO) seems to be one of the main contributors to this vascular alteration, since elimination of the endothelium or inhibition of its synthesis corrects it. The mechanism by which NO interferes with the contractile apparatus in smooth muscle cells seems to be related to a direct effect on calcium entry from the extracellular space and release from the internal stores.
Export Options
About this article
Cite this article as:
Atucha M. Noemi, Nadal Javi A. F., Iyu David, Alcaraz Antonia, Rodriguez-Barbero Alicia, Ortiz Clara M., Lopez-Novoa Miguel Jose and Garcia-Estan Joaquin, Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773889
DOI https://dx.doi.org/10.2174/1570161052773889 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians 2016 Guidelines
Current Drug Metabolism Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews Dopamine and Vascular Dynamics Control: Present Status and Future Perspectives
Current Neurovascular Research Cannabinoid Receptor Activation and the Endocannabinoid System in the Gastrointestinal Tract
Current Neuropharmacology Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry Clinical Trials for Acute Kidney Injury: Design Challenges and Possible Solutions
Current Drug Targets Induction and Amelioration of Environmental Stress in Isolated Islets Until Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Hypotensive Natural Products: Current Status
Mini-Reviews in Medicinal Chemistry Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets TNFα as Therapeutic Target: New Drugs, More Applications
Current Drug Targets - Inflammation & Allergy Triphala in Prevention of Dental Caries and as an Antimicrobial in Oral Cavity- A Review
Infectious Disorders - Drug Targets Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs
Current Topics in Medicinal Chemistry Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials